Drugs / GLPG5101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06561425 | Mar 2022 → May 2026 | B-cell non-Hodgkin lymphoma | Lakefront Biotherapeutics NV | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLPG5101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06561425 ↗ |
| Modality | Cell therapy | “Autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy” NCT06561425 ↗ |
| Route | Intravenous | “GLPG5101 intravenous (IV) cell suspension for infusion” NCT06561425 ↗ |
| Target | CD19 | “Autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy” NCT06561425 ↗ |